{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:55:21Z","timestamp":1782917721327,"version":"3.54.5"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41375-026-02973-8","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:17:26Z","timestamp":1778591846000},"page":"1494-1501","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement"],"prefix":"10.1038","volume":"40","author":[{"given":"Benoit","family":"Ducourneau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2337-8693","authenticated-orcid":false,"given":"Arnaud","family":"Pages","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Struski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Decamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3925-7391","authenticated-orcid":false,"given":"Emmanuel","family":"Raffoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Berthon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2808-4843","authenticated-orcid":false,"given":"Laur\u00e8ne","family":"Fenwarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Marmouset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Pautas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6745-1127","authenticated-orcid":false,"given":"Thomas","family":"Cluzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4073-1559","authenticated-orcid":false,"given":"Delphine","family":"Lebon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madalina","family":"Uzunov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Pereyra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00ebl","family":"Heiblig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Val\u00e8re","family":"Malfuson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Farnault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0119-3548","authenticated-orcid":false,"given":"Pierre-Yves","family":"Dumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0947-2789","authenticated-orcid":false,"given":"Julia","family":"Hieulle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1084-2781","authenticated-orcid":false,"given":"Sarah","family":"Bertoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Chantepie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9744-4470","authenticated-orcid":false,"given":"Nathalie","family":"Auger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0992-8377","authenticated-orcid":false,"given":"Audrey","family":"Bidet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Joelle","family":"Mozziconacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9154-1085","authenticated-orcid":false,"given":"Augustin","family":"Boudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7891-5727","authenticated-orcid":false,"given":"Isabelle","family":"Luquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laureen","family":"Chat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5644-926X","authenticated-orcid":false,"given":"Romain","family":"Loyaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"El-Mur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Clappier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Gardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7777-5216","authenticated-orcid":false,"given":"Mathilde","family":"Hunault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8126-4942","authenticated-orcid":false,"given":"St\u00e9phane","family":"De Botton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5479-0261","authenticated-orcid":false,"given":"Arnaud","family":"Pigneux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Penther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0928-0753","authenticated-orcid":false,"given":"Eric","family":"Delabesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2139-6262","authenticated-orcid":false,"given":"Raphael","family":"Itzykson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Preudhomme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Dombret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3332-4525","authenticated-orcid":false,"given":"Christian","family":"Recher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3927-1022","authenticated-orcid":false,"given":"Nicolas","family":"Duployez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0934-294X","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Micol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"2973_CR1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2973_CR2","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1182\/blood.2020007093","volume":"136","author":"NL Michmerhuizen","year":"2020","unstructured":"Michmerhuizen NL, Klco JM, Mullighan CG. Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies. Blood. 2020;136:2275\u201389.","journal-title":"Blood"},{"key":"2973_CR3","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1182\/blood.2021012806","volume":"139","author":"EB Heikamp","year":"2022","unstructured":"Heikamp EB, Henrich JA, Perner F, Wong EM, Hatton C, Wen Y, et al. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. Blood. 2022;139:894\u2013906.","journal-title":"Blood"},{"key":"2973_CR4","doi-asserted-by":"publisher","first-page":"e935","DOI":"10.1097\/HS9.0000000000000935","volume":"7","author":"M Rasouli","year":"2023","unstructured":"Rasouli M, Blair H, Troester S, Szoltysek K, Cameron R, Ashtiani M, et al. The MLL-Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML. HemaSphere. 2023;7:e935.","journal-title":"HemaSphere"},{"key":"2973_CR5","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/sj.leu.2404130","volume":"20","author":"SP Romana","year":"2006","unstructured":"Romana SP, Radford-Weiss I, Ben Abdelali R, Schluth C, Petit A, Dastugue N, et al. NUP98 rearrangements in hematopoietic malignancies: a study of the Groupe Francophone de Cytog\u00e9n\u00e9tique H\u00e9matologique. Leukemia. 2006;20:696\u2013706.","journal-title":"Leukemia"},{"key":"2973_CR6","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.3324\/haematol.2022.281653","volume":"108","author":"EJM Bertrums","year":"2023","unstructured":"Bertrums EJM, Smith JL, Harmon L, Ries RE, Wang YCJ, Alonzo TA, et al. Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia. Haematologica. 2023;108:2044\u201358.","journal-title":"Haematologica"},{"key":"2973_CR7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/leu.2016.267","volume":"31","author":"S Struski","year":"2017","unstructured":"Struski S, Lagarde S, Bories P, Puiseux C, Prade N, Cuccuini W, et al. NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis. Leukemia. 2017;31:565\u201372.","journal-title":"Leukemia"},{"key":"2973_CR8","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1182\/blood-2014-04-570929","volume":"124","author":"F Ostronoff","year":"2014","unstructured":"Ostronoff F, Othus M, Gerbing RB, Loken MR, Raimondi SC, Hirsch BA, et al. NUP98\/NSD1 and FLT3\/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. Blood. 2014;124:2400\u20137.","journal-title":"Blood"},{"key":"2973_CR9","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1609128","volume":"2019","author":"N Niktoreh","year":"2019","unstructured":"Niktoreh N, Walter C, Zimmermann M, Von Neuhoff C, Von Neuhoff N, Rasche M, et al. Mutated WT1, FLT3-ITD, and NUP98-NSD1 Fusion in Various Combinations Define a Poor Prognostic Group in Pediatric Acute Myeloid Leukemia. J Oncol. 2019;2019:1609128.","journal-title":"J Oncol"},{"key":"2973_CR10","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1182\/blood-2011-04-346643","volume":"118","author":"IHIM Hollink","year":"2011","unstructured":"Hollink IHIM, Van Den Heuvel-Eibrink MM, Arentsen-Peters STCJM, Pratcorona M, Abbas S, Kuipers JE, et al. NUP98\/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood. 2011;118:3645\u201356.","journal-title":"Blood"},{"key":"2973_CR11","doi-asserted-by":"crossref","unstructured":"Sajjan S, Oertling EE, Fuda F, Gagan J, Koduru P, Garcia R, et al. Clinicopathologic and Molecular Characterization of NUP98-Rearranged Acute Leukemias. Int J Lab Hematol. 2025;47:445\u201353.","DOI":"10.1111\/ijlh.14422"},{"key":"2973_CR12","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/leu.2012.249","volume":"27","author":"F Thol","year":"2013","unstructured":"Thol F, K\u00f6lking B, Hollink IHI, Damm F, Van Den Heuvel-Eibrink MM, Michel Zwaan C, et al. Analysis of NUP98\/NSD1 translocations in adult AML and MDS patients. Leukemia. 2013;27:750\u20134.","journal-title":"Leukemia"},{"key":"2973_CR13","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1182\/bloodadvances.2023012479","volume":"8","author":"JS Heald","year":"2024","unstructured":"Heald JS, L\u00f3pez AM, Pato ML, Ruiz-Xivill\u00e9 N, Cabez\u00f3n M, Zamora L, et al. Identification of novel NUP98 fusion partners and comutations in acute myeloid leukemia: an adult cohort study. Blood Adv. 2024;8:2691\u20134.","journal-title":"Blood Adv"},{"key":"2973_CR14","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1182\/bloodadvances.2024012960","volume":"8","author":"N Kim","year":"2024","unstructured":"Kim N, Choi YJ, Cho H, Jang JE, Lee ST, Song J, et al. NUP98 is rearranged in 5.0% of adult East Asian patients with AML. Blood Adv. 2024;8:5122\u20135.","journal-title":"Blood Adv"},{"key":"2973_CR15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00277-022-05047-8","volume":"102","author":"H Sun","year":"2023","unstructured":"Sun H, Yan H, Yan Z, Zhu Y, Yang G, Zhang S. Acute myeloid leukemia patients with NUP98::NSD1 showing initially poor treatment response can benefit from FLT3 inhibitors and venetoclax as well as HSCT. Ann Hematol. 2023;102:473\u20135.","journal-title":"Ann Hematol"},{"key":"2973_CR16","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/ejh.14055","volume":"111","author":"T Miyajima","year":"2023","unstructured":"Miyajima T, Onozawa M, Yoshida S, Miyashita N, Kimura H, Takahashi S, et al. Clinical implications of NUP98::NSD1 fusion at diagnosis in adult FLT3-ITD positive AML. Eur J Haematol. 2023;111:620\u20137.","journal-title":"Eur J Haematol"},{"key":"2973_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01066-y","volume":"14","author":"J Tian","year":"2024","unstructured":"Tian J, Zhu Y, Li J, Yang G, Weng X, Huang T, et al. The landscape of NUP98 rearrangements clinical characteristics and treatment response from 1491 acute leukemia patients. Blood Cancer J. 2024;14:81.","journal-title":"Blood Cancer J"},{"key":"2973_CR18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/leu.2012.230","volume":"27","author":"A Fasan","year":"2013","unstructured":"Fasan A, Haferlach C, Alpermann T, Kern W, Haferlach T, Schnittger S. A rare but specific subset of adult AML patients can be defined by the cytogenetically cryptic NUP98-NSD1 fusion gene. Leukemia. 2013;27:245\u20138.","journal-title":"Leukemia"},{"key":"2973_CR19","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/bjh.19962","volume":"206","author":"C Frerich","year":"2025","unstructured":"Frerich C, Li P, Raess PW, Dunlap J, Lachowiez C, Solis-Ruiz J, et al. Landscape of somatic mutations and clonal evolution in NUP98-rearranged adult acute myeloid leukaemia. Br J Haematol. 2025;206:1097\u2013102.","journal-title":"Br J Haematol"},{"key":"2973_CR20","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne S, Pautas C, Terr\u00e9 C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet Lond Engl. 2012;379:1508\u201316.","journal-title":"Lancet Lond Engl"},{"key":"2973_CR21","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1182\/blood.2019003471","volume":"135","author":"E Fournier","year":"2020","unstructured":"Fournier E, Duployez N, Ducourneau B, Raffoux E, Turlure P, Caillot D, et al. Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia. Blood. 2020;135:542\u20136.","journal-title":"Blood"},{"key":"2973_CR22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/sj.leu.2404521","volume":"21","author":"X Thomas","year":"2007","unstructured":"Thomas X, Raffoux E, De Botton S, Pautas C, Arnaud P, De Revel T, et al. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia. 2007;21:453\u201361.","journal-title":"Leukemia"},{"key":"2973_CR23","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1182\/blood.2020005524","volume":"137","author":"L Fenwarth","year":"2021","unstructured":"Fenwarth L, Thomas X, De Botton S, Duployez N, Bourhis JH, Lesieur A, et al. A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia. Blood. 2021;137:524\u201332.","journal-title":"Blood"},{"key":"2973_CR24","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/leu.2015.177","volume":"30","author":"P Ruminy","year":"2016","unstructured":"Ruminy P, Marchand V, Buchbinder N, Larson T, Joly B, Penther D, et al. Multiplexed targeted sequencing of recurrent fusion genes in acute leukaemia. Leukemia. 2016;30:757\u201360.","journal-title":"Leukemia"},{"key":"2973_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-022-04983-6","volume":"23","author":"A Boudry","year":"2022","unstructured":"Boudry A, Darmon S, Duployez N, Figeac M, Geffroy S, Bucci M, et al. Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r. BMC Bioinf. 2022;23:448.","journal-title":"BMC Bioinf"},{"key":"2973_CR26","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.1182\/bloodadvances.2021004322","volume":"5","author":"J Lambert","year":"2021","unstructured":"Lambert J, Lambert J, Thomas X, Marceau-Renaut A, Micol J-B, Renneville A, et al. Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML. Blood Adv. 2021;5:5258\u201368.","journal-title":"Blood Adv"},{"key":"2973_CR27","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, Dinardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2973_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/sim.4780030106","volume":"3","author":"R Simon","year":"1984","unstructured":"Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med. 1984;3:35\u201344.","journal-title":"Stat Med"},{"key":"2973_CR29","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1182\/blood.V98.4.1264","volume":"98","author":"RJ Jaju","year":"2001","unstructured":"Jaju RJ, Fidler C, Haas OA, Strickson AJ, Watkins F, Clark K, et al. A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia. Blood. 2001;98:1264\u20137.","journal-title":"Blood"},{"key":"2973_CR30","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1182\/blood.V89.11.3936","volume":"89","author":"Y Arai","year":"1997","unstructured":"Arai Y, Hosoda F, Kobayashi H, Arai K, Hayashi Y, Kamada N, et al. The inv(11)(p15q22) chromosome translocation of de novo and therapy-related myeloid malignancies results in fusion of the nucleoporin gene, NUP98, with the putative RNA helicase gene, DDX10. Blood. 1997;89:3936\u201344.","journal-title":"Blood"},{"key":"2973_CR31","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/gcc.20308","volume":"45","author":"LJCM Van Zutven","year":"2006","unstructured":"Van Zutven LJCM, Onen E, Velthuizen SCJM, Van Drunen E, Von Bergh ARM, Van Den Heuvel-Eibrink MM, et al. Identification of NUP98 abnormalities in acute leukemia: JARID1A (12p13) as a new partner gene. Genes Chromosomes Cancer. 2006;45:437\u201346.","journal-title":"Genes Chromosomes Cancer"},{"key":"2973_CR32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/ng0296-159","volume":"12","author":"J Borrow","year":"1996","unstructured":"Borrow J, Shearman AM, Stanton VP, Becher R, Collins T, Williams AJ, et al. The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9. Nat Genet. 1996;12:159\u201367.","journal-title":"Nat Genet"},{"key":"2973_CR33","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1182\/blood.V94.9.3258","volume":"94","author":"HG Ahuja","year":"1999","unstructured":"Ahuja HG, Felix CA, Aplan PD. The t(11;20)(p15;q11) chromosomal translocation associated with therapy-related myelodysplastic syndrome results in an NUP98-TOP1 fusion. Blood. 1999;94:3258\u201361.","journal-title":"Blood"},{"key":"2973_CR34","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/sj.leu.2403565","volume":"19","author":"C Gervais","year":"2005","unstructured":"Gervais C, Mauvieux L, Perrusson N, H\u00e9lias C, Struski S, Leymarie V, et al. A new translocation t(9;11)(q34;p15) fuses NUP98 to a novel homeobox partner gene, PRRX2, in a therapy-related acute myeloid leukemia. Leukemia. 2005;19:145\u20138.","journal-title":"Leukemia"},{"key":"2973_CR35","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1182\/blood.V94.2.741","volume":"94","author":"T Nakamura","year":"1999","unstructured":"Nakamura T, Yamazaki Y, Hatano Y, Miura I. NUP98 is fused to PMX1 homeobox gene in human acute myelogenous leukemia with chromosome translocation t(1;11)(q23;p15). Blood. 1999;94:741\u20137.","journal-title":"Blood"},{"key":"2973_CR36","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2010-04-277806","volume":"116","author":"S Kaltenbach","year":"2010","unstructured":"Kaltenbach S, Soler G, Barin C, Gervais C, Bernard OA, Penard-Lacronique V, et al. NUP98-MLL fusion in human acute myeloblastic leukemia. Blood. 2010;116:2332\u20135.","journal-title":"Blood"},{"key":"2973_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.20","volume":"3","author":"G Soler","year":"2013","unstructured":"Soler G, Kaltenbach S, Dobbelstein S, Broccardo C, Radford I, Mozziconacci MJ, et al. Identification of GSX2 and AF10 as NUP98 partner genes in myeloid malignancies. Blood Cancer J. 2013;3:e124.","journal-title":"Blood Cancer J"},{"key":"2973_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-12-5","volume":"12","author":"S Lisboa","year":"2013","unstructured":"Lisboa S, Cerveira N, Bizarro S, Correia C, Vieira J, Torres L, et al. POU1F1 is a novel fusion partner of NUP98 in acute myeloid leukemia with t(3;11)(p11;p15). Mol Cancer. 2013;12:5.","journal-title":"Mol Cancer"},{"key":"2973_CR39","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1182\/blood.V94.6.2072","volume":"94","author":"DJ Hussey","year":"1999","unstructured":"Hussey DJ, Nicola M, Moore S, Peters GB, Dobrovic A. The (4;11)(q21;p15) translocation fuses the NUP98 and RAP1GDS1 genes and is recurrent in T-cell acute lymphocytic leukemia. Blood. 1999;94:2072\u20139.","journal-title":"Blood"},{"key":"2973_CR40","first-page":"4269","volume":"58","author":"SZ Raza-Egilmez","year":"1998","unstructured":"Raza-Egilmez SZ, Jani-Sait SN, Grossi M, Higgins MJ, Shows TB, Aplan PD. NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia. Cancer Res. 1998;58:4269\u201373.","journal-title":"Cancer Res"},{"key":"2973_CR41","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/s41375-023-01913-0","volume":"37","author":"T Matsukawa","year":"2023","unstructured":"Matsukawa T, Yin M, Nigam N, Negi V, Li L, Small D, et al. NUP98::Nsd1 and FLT3-ITD collaborate to generate acute myeloid leukemia. Leukemia. 2023;37:1545\u20138.","journal-title":"Leukemia"},{"key":"2973_CR42","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1182\/blood.2019002697","volume":"135","author":"K D\u00f6hner","year":"2020","unstructured":"D\u00f6hner K, Thiede C, Jahn N, Panina E, Gambietz A, Larson RA, et al. Impact of NPM1\/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood. 2020;135:371\u201380.","journal-title":"Blood"},{"key":"2973_CR43","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/s41409-023-02030-3","volume":"58","author":"Y Shen","year":"2023","unstructured":"Shen Y, Zhang T, Zhang L, Zhen S, Chen Z, Zhang R, et al. Allogeneic stem cell transplantation can prolong the survival of patients with NUP98-rearranged acute myeloid leukemia. Bone Marrow Transpl. 2023;58:1149\u201351.","journal-title":"Bone Marrow Transpl"},{"key":"2973_CR44","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, \u017d\u00e1k P, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2023;401:1571\u201383.","journal-title":"Lancet Lond Engl"},{"key":"2973_CR45","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019;381:1728\u201340.","journal-title":"N Engl J Med"},{"key":"2973_CR46","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S1470-2045(15)00362-9","volume":"16","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig C, Serve H, H\u00fcttmann A, Noppeney R, M\u00fcller-Tidow C, Krug U, et al. Study Alliance Leukaemia. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16:1691\u20139.","journal-title":"Lancet Oncol"},{"key":"2973_CR47","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","volume":"36","author":"AV Krivtsov","year":"2019","unstructured":"Krivtsov AV, Evans K, Gadrey JY, Eschle BK, Hatton C, Uckelmann HJ, et al. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. Cancer Cell. 2019;36:660\u2013673.e11.","journal-title":"Cancer Cell"},{"key":"2973_CR48","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1182\/blood.2020006575","volume":"136","author":"H Miao","year":"2020","unstructured":"Miao H, Kim E, Chen D, Purohit T, Kempinska K, Ropa J, et al. Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations. Blood. 2020;136:2958\u201363.","journal-title":"Blood"},{"key":"2973_CR49","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1182\/blood.2020005037","volume":"136","author":"MM Dzama","year":"2020","unstructured":"Dzama MM, Steiner M, Rausch J, Sasca D, Sch\u00f6nfeld J, Kunz K, et al. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition. Blood. 2020;136:2442\u201356.","journal-title":"Blood"},{"key":"2973_CR50","doi-asserted-by":"crossref","unstructured":"Zeidan AM Ziftomenib combined with intensive induction (7+3) in newly diagnosed NPM1-m or KMT2A-r acute myeloid leukemia: Interim phase 1a results from KOMET-007. Oral Abstract #214. 66th American Society of Hematology Annual Meeting and Exposition, 2024; San Diego, US.","DOI":"10.1182\/blood-2024-198218"},{"key":"2973_CR51","unstructured":"Fathi AT Ziftomenib combined with venetoclax\/azacitidine in relapsed\/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Interim phase 1a results from KOMET-007. Oral Abstract #2880. 66th American Society of Hematology Annual Meeting and Exposition, San Diego, US."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02973-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02973-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02973-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:22:40Z","timestamp":1782915760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02973-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2973"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02973-8","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J-B.M has received Honoraria from Jazz Pharmaceuticals, Astellas Pharma, SERVIER, Consulting or Advisory Role from AbbVie, Gilead Sciences, Travel support from AbbVie. SB has received Honoraria from Abbvie, Astellas, BMS, Daiichi-Sankyo, J&J, Novartis, Pfizer, Servier. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}